A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients with Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

ID Number 14-0403

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called CDX-1127. An experimental drug is one that is being tested and is not available to buy on the market. A phase 1 study is designed to determine the side effects associated with an experimental study drug and how much of the experimental study drug can be given safely (i.e., the “maximum tolerated dose”). This study will also look at whether CDX-1127 is effective in activating the immune system and fighting cancer. This is the first study in which CDX-1127 is being given to people.

Contact Information
(212) 824-7309

Recruiting Patients: No